Nitric oxide synthase in CHF
We read with great interest the paper by Comini et al. [1] which demonstrates the induction of inducible nitric oxide synthase (iNOS) expression in circulating monocytes of patients with chronic heart failure. As we believe this paper reports upon a very important aspect of current research, we would like to comment on two aspects which we think are of special interest.
Firstly, the activation of the nitric oxide (NO)/cGMP pathway in the heart can be induced experimentally by relatively high concentrations of TNF and the results by Comini et al. [1] strongly support such a potential pathophysiological link in a clinical setting. There is, however, evidence from in vitro studies of NO-independent cardiodepression at lower, pathophysiologically more relevant concentrations. In this respect, the effects of TNF on the heart vary with regard to the kinetics of the process [2] . Immediate negative inotropic effects of TNF were mediated by sphingosine [3] and included suppression of the calcium transcient [4] . Chronic administration of TNF caused a reduction in the synthesis of the precursors of the phosphoinositide pathway and inhibited pyruvate dehydrogenase activity and mitochondrial function [5] . Secondary cytokines induced by TNF or endotoxin [6] in cardiomyocytes through the CD14 pathway [7] , as mentioned by the authors, could contribute to cardiodepression independent of NO. Whether the direct activation of apoptotic signals by TNF is involved in cardiodepression remains unclear [8] [9] [10] . Cytokine mediated chronotropic effects on cardiomyocytes were both NOdependent and NO-independent [11, 12] . Finally, TNF also impairs and abolishes, in an NO-independent manner, inotropic responses of rat cardiomyocytes to the cardiac glycoside ouabain and to 1 -adrenoreceptor agonists [13, 14] . In summary, a complex picture of the contribution of TNF , either by NO-dependent or NOindependent mechanisms, is evolving and more data are required to complete our understanding.
Comini et al. [1] did not find an association between cytotoxic TNF and iNOS expression. This may be partly due to methodological difficulties using a bioactive cytotoxic assay. This method requires the culture of cells in fetal calf serum, which is a fundamental point of criticism as all sera are potentially contaminated with cytokines, leading to either a potentiation or reduction of TNF -mediated cytotoxicty [15, 16] . To confirm specific TNF -mediated cytotoxicity, the authors tested the bioassay with a recombinant TNF antibody, but unfortunately the results have not been reported. The addition of actinomycin D, a transcription inhibitor, usually increases sensitivity and reduces the incubation time of the bioassay. Espevik et al. [17] , however, failed to increase further the highly sensitive cell line WEHI 164 by treating the cells with actinoymycin D. This, in turn, may suggest, that the incubation time of 24 h, as used by Comini et al. [1] might have been too short. As the bioassay only measures bioactive, trimeric TNF , this procedure has the potential to exclude the usual ELISA bias to recognize both trimeric (bioactive) and recombinant monomeric (bioactive or neutral?) TNF (personal communication with the manufacturers). We are not aware of any ELISA test kit that only recognizes trimeric, i.e. bioactive TNF . 
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We agree with the authors that the cytokine network plays an important role in congestive heart failure (CHF) [1, 2] . In this complex scenario, tumour necrosis factor alpha (TNF ) in particular reflects a primary role as a modulator of myocardial contractility either via NO-dependent (usually ascribed to inducible NOS induction) or NO-independent mechanisms.
Because both of these mechanisms exert marked cardiodepression, we suggest they may represent complementary aspects of the same issue. Indeed, transgenic mice for TNF production in cardiac myocytes suggest that cytokine production is sufficient to induce severe CHF, supporting the causal role of TNF in the pathogenesis of the disease [3] . A recent paper on patients with mechanical assistance for CHF points out the correlation between intracardiac levels of TNF and the recovery of mechanical function [4] . However, our paper entitled 'Induction of functional nitric oxide synthase in monocytes of patients with congestive heart failure' [5] evaluated the role of TNF in iNOS induction in peripheral monocytes, and we can only speculate on the control mechanisms of cardiac function (infiltrated macrophages and iNOS induction). Alternatively, we can hypothesize that iNOS induced in monocytes can modulate vascular reactivity and blood cells/ endothelium interaction.
We entirely agree with the authors that the bioactive cytotoxic assay on WEHI 164 cells implies some technical difficulties due, for example, to the use of fetal calf serum, usually not tested for cytokine contamination. However, this potential negative impact is minimized by the fact that both standard curve and samples are prepared in the same culture medium (RPMI 1640) enriched with FCS, providing data affected by the same bias.
To overcome the limitation of WEHI bioassay, we set up a new bioassay using human umbilical vein endothelial cells (HUVEC s ) instead of fibroblasts. As reported by Agnoletti et al. [2] , TNF from CHF patients (NYHA class IV) when administered directly to HUVEC s , mimicking a physiopathological cytotoxic assay, exerts a significant apoptotic effect on these cells, underlying a primary role of TNF in inducing cytotoxicity.
To confirm specific TNF -mediated cytotoxicity, we tested the bioassay with a recombinant TNF antibody and indicated in the legend of Table 2 the values obtained by subtracting aspecific from total TNF cytotoxic activity (specific TNF activity). The TNF -independent cytotoxicity was relevant and highly variable, ranging from 40 to 100% of the total TNF cytotoxic activity, and could not be correlated with the NYHA class.
Concerning the length of the WEHI 164 bioassay, we observed that, under our assay conditions, a high proportion of these cells die after 24 h incubation with TNF standard solutions. Thus, longer incubation may not be necessary to kill the cells. However, we do not know whether the increase in the incubation time of the assay could ameliorate the assay detectability.
Finally, we agree that bioassays and ELISAs may differentially detect trimeric and monomeric TNF , as the latter appears to be biologically inactive [6] . It would be desirable to have an assay on hand that could detect trimeric TNF only. The availability of an assay specific for trimeric TNF has been reported in the literature [7] . However, although this assay was proven to be suitable for biochemical studies on TNF trimer-monomer transitions, could not measure the trimeric TNF in serum samples. 
Classification of acute MI
Porela et al. [1] proposed that the definition for epidemiological classification of acute myocardial infarction could be based solely on a 'specific cardiac marker' such as creatine kinase MB mass. These suggestions exhibit a touching faith in the abilities of clinical biochemistry by the authors but betray a certain lack of understanding.
1. Reference ranges and diagnostic cut offs are set by reference to
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